Anika Therapeutics (ANIK) Amortizatization of Intangibles (2019 - 2026)
Anika Therapeutics (ANIK) reported Amortizatization of Intangibles of $464000.0 for Q1 2026, up 122.01% year-over-year from $209000.0 in Q1 2025, and down 72.77% quarter-over-quarter from $1.7 million in Q4 2025.
Anika Therapeutics (ANIK) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 8 years of Amortizatization of Intangibles data on file, last reported at $464000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $464000.0, up 122.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (up 107.34% YoY), and the FY2025 annual result was $2.1 million, up 66.61% from the prior year.
- Amortizatization of Intangibles eased to $464000.0 in Q1 2026 per ANIK's latest filing, from $1.7 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $6.1 million in Q4 2023 and troughed at -$1.1 million in Q2 2022.
- A 5-year average of $1.1 million and a median of $547000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 625.93% in 2025 and fell as far as 221.16% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $1.9 million in 2022, then soared by 216.03% to $6.1 million in 2023, then tumbled by 105.27% to -$324000.0 in 2024, then surged by 625.93% to $1.7 million in 2025, then plunged by 72.77% to $464000.0 in 2026.
- Business Quant data shows ANIK's Amortizatization of Intangibles at $464000.0 in Q1 2026, $1.7 million in Q4 2025, and -$710000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 1.30 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 242,000.00 |
| 10 | Anika Therapeutics | 200.80 Mn | 134.01 Mn | 19.00 Mn | 464,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 464,000.00 |
| Mar 31, 2026 | 464,000.00 |
| Dec 31, 2025 | 1.70 Mn |
| Dec 31, 2025 | 1.70 Mn |
| Sep 30, 2025 | -710,000.00 |
| Sep 30, 2025 | -710,000.00 |
| Jun 30, 2025 | 858,000.00 |
| Jun 30, 2025 | 858,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Dec 31, 2024 | -324,000.00 |
| Dec 31, 2024 | -324,000.00 |
| Sep 30, 2024 | 586,000.00 |
| Sep 30, 2024 | 586,000.00 |
| Jun 30, 2024 | 646,000.00 |
| Jun 30, 2024 | 646,000.00 |
| Mar 31, 2024 | 329,000.00 |
| Mar 31, 2024 | 329,000.00 |
| Dec 31, 2023 | 6.15 Mn |
| Dec 31, 2023 | 6.15 Mn |